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ABSTRACT
Objectives This study aimed to determine the 
prevalence of ultrasound- detected tendon abnormalities 
in healthy subjects (HS) across the age range.
Methods Adult HS (age 18–80 years) were recruited 
in 23 international Outcome Measures in Rheumatology 
ultrasound centres and were clinically assessed to exclude 
inflammatory diseases or overt osteoarthritis before 
undergoing a bilateral ultrasound examination of digit 
flexors (DFs) 1–5 and extensor carpi ulnaris (ECU) tendons 
to detect the presence of tenosynovial hypertrophy (TSH), 
tenosynovial power Doppler (TPD) and tenosynovial effusion 
(TEF), usually considered ultrasound signs of inflammatory 
diseases. A comparison cohort of patients with rheumatoid 
arthritis (RA) was taken from the Birmingham Early Arthritis 
early arthritis inception cohort.
Results 939 HS and 144 patients with RA were 
included. The majority of HS (85%) had grade 0 for 
TSH, TPD and TEF in all DF and ECU tendons examined. 
There was a statistically significant difference in the 
proportion of TSH and TPD involvement between HS and 
subjects with RA (HS vs RA p<0.001). In HS, there was 
no difference in the presence of ultrasound abnormalities 
between age groups.
Conclusions Ultrasound- detected TSH and TPD 
abnormalities are rare in HS and can be regarded as 
markers of active inflammatory disease, especially in 
newly presenting RA.
INTRODUCTION
Tenosynovitis (TS) of hand and wrist tendons is 
common in early untreated inflammatory polyar-
thritis.1 However, clinical examination alone may 
not detect this pathology,2 especially as conven-
tional rheumatoid arthritis (RA) disease activity 
scoring systems focus on joints, not tendons. The 
use of MRI and ultrasound examination is more 
sensitive and has shown that the prevalence of 
detecting TS in patients with early RA is higher than 
by physical examination alone.3
Key messages
What is already known about this subject?
 ► Little is known about the prevalence of 
sonographic tenosynovial abnormalities in 
healthy subjects (HS) across the age range.
What does this study add?
 ► This is the largest cohort of healthy subjects 
with tendons scanned by ultrasound.
 ► There is very low prevalence of tendon synovial 
hypertrophy or power Doppler abnormalities in 
tendons of HS even in old age.
 ► Ultrasound- detected inflammation in digit 
flexor and extensor carpi ulnaris tendons in 
patients suspected to be in the early stages 
of rheumatoid arthritis (RA) should not be 
discounted as physiological, even in older age.
How might this impact on clinical practice or 
future developments?
 ► Ultrasound- detected tenosynovial abnormalities 
can be regarded as robust findings in the 
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There has been extensive focus on the sensitivity and role 
of ultrasound in detecting subclinical synovial inflammation.4 5 
Ultrasound has been shown to be highly sensitive in the detec-
tion of tenosynovial inflammation, with recent studies demon-
strating that ultrasound- detected hand and wrist TS has a role 
in predicting outcome in early RA and flare in clinical remis-
sion.6 7
Although recent studies using MRI have focused on the prev-
alence of tendon abnormalities in healthy subjects (HS),8 there 
are limited data on the prevalence of ultrasound- detected ‘TS’ 
abnormalities in HS, with data arising from small comparison 
cohorts (ie, case–control studies focused on patients with rheu-
matic diseases). Furthermore, current studies were not focused 
on the prevalence of sonographic tendon abnormalities in HS 
within the age range of 40–70 years when RA commonly pres-
ents.9 The prevalence of such abnormalities therefore remains 
unknown in this group.
The objective of this Outcome Measures in Rheumatology 
(OMERACT) ultrasound study was therefore to determine the 
prevalence of ultrasound- detected tendon abnormalities charac-
terising the presence of TS in HS according to the age range.
METHODS
Adult HS (18–80 years) were recruited between August 2017 
and December 2018 in 23 ultrasound centres in 14 countries 
with experience of participating in OMERACT ultrasound 
studies. To ensure a wide range of age coverage, recruitment 
was obtained from a large range of populations: university or 
hospital research staff, health service workers, students, volun-
teers from local advertising or national cohorts such as the 
Birmingham 1000 Elders group10 in the UK. Exclusion criteria 
were current or previous history of any form of inflammatory 
arthritis, joint trauma of hands or wrist in the previous month; 
hand or wrist pain ≥10/100 on the Visual Analogue Scale; hand 
osteoarthritis according to American College of Rheumatology 
(ACR) criteria11; history of infection; and recent or current use 
of medications that may affect ultrasound assessment (see online 
supplemental table 1). An additional 12 HS were excluded after 
data collection but before ultrasound analysis due to autoim-
mune, infectious or musculoskeletal conditions identified from 
medical history that could confound the results. Demographic 
data including body mass index (BMI) were collected. Metacar-
pophalangeal, proximal interphalangeal, metatarsophalangeal 
and wrist joints were clinically examined by an independent 
assessor in each centre, and subjects were excluded if synovitis 
was found.
Ultrasound assessment of bilateral digit flexors (DFs) 1–5 and 
extensor carpi ulnaris (ECU) tendons was performed using a 
multiplanar approach. The presence of hypoechoic tenosyno-
vial hypertrophy (TSH) and power Doppler signal within teno-
synovial power Doppler (TPD) was defined and graded using 
the OMERACT ultrasound scoring system for TS in RA.12 The 
ungraded presence of tenosynovial effusion (TEF) was recorded. 
Adequate gel was used to avoid compression. Views were 
recorded according to European League Against Rheumatism 
(EULAR) standard reference scan guidelines.13 Musculoskeletal 
specific preset parameters were used to optimise imaging for 
greyscale and power Doppler and reduce variability. Details of 
probes, machines and experience of sonographers in all centres 
can be found in online supplemental table 2. Quality and grading 
of recorded images were confirmed by a review of all images for 
the first HS recruited in each centre by an experienced blinded 
independent assessor (IS) in the hub centre. Any disagreement 
was then fed back to the centre and consensus was achieved to 
ensure reliability in subsequent scans.
Data for a comparison cohort of DMARD- naive patients 
presenting as patients with new early arthritis with RA fulfilling 
ACR- EULAR 201014 and/or 1987 criteria15 at presentation 
were extracted from the Birmingham Early Arthritis (BEACON) 
inception cohort.6 The following data were collected: 68 tender 
and 66 swollen clinical counts, age, sex, symptom duration, early 
morning stiffness duration, medication, erythrocyte sedimenta-
tion rate (ESR), C reactive protein (CRP), rheumatoid factor and 
anti- citrullinated protein antibody status. This cohort underwent 
identical baseline tendon ultrasound assessment except for the 
presence of TEF.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics V.26. 
Significance for the binary variable gender was assessed using 
Fisher’s exact test. The continuous variables age and BMI (for all 
subjects) and early morning stiffness, CRP and joint counts (for 
patients with RA) were not normally distributed; significance 
was therefore assessed using the Kruskal- Wallis test. The tendon 
gradings were dichotomised into either present (grades 1–3) or 
absent (grade 0). Fisher’s exact test was used to compare the 
proportions of grade 1–3 TSH, TPD or TEF between age groups 
in HS, and between HS and patients with RA.
RESULTS
One thousand and forty- nine HS were recruited and 939 HS 
were included after exclusions of subjects with protocol devi-
ations (see flowchart in online supplemental figure 1). Baseline 
data for 144 patients with RA were randomly extracted from the 
BEACON database and matched with a cohort of 144 HS by age, 
sex and smoking status where possible. Table 1 shows the demo-
graphic and ultrasound characteristics of the two populations. 
Full ultrasound grading results are available in online supple-
mental table 2 and example of grading in online supplemental 
figure 2.
Healthy subjects
The median age of HS was 43 years (30–57). HS were grouped 
into three age groups: HS Y (young, 18–39 years) HS M (middle, 
40–59 years) and HS O (old, 60–80 years) for analysis. The 
majority of volunteer HS were healthcare professionals (423, 
45.0%). Other occupational groups included clerical staff (156, 
16.6%), students (95, 10.1%), manual workers (68, 7.2%) and 
teachers (34, 3.6%).
A total of 11 237 tendons were scanned; 98% of these tendons 
were grade 0 for TSH, TPD and TEF (online supplemental table 
3). The distribution of tendon abnormalities, when found, was 
symmetrical with no significant difference between right and left 
hands (online supplemental table 4). TEF was more frequently 
detected than TSH or TPD (p<0.001) (online supplemental 
table 5).
The majority (791/939, 84.2%) of HS presented grade 0 
overall for all ultrasound lesions examined (TSH, TPD and TEF) 
in all DF 1–5 and ECU tendons. In particular 99% (931/939) of 
HS had grade 0 for TPD in all tendons scanned. There were no 
statistically significant differences between age groups (table 1 
and figure 1).
Abnormalities were detected in 148 individuals across 939 HS 
and were of grade 1 severity, with the exception of one grade 2 
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more grade ≥1 for TSH than the DF 1–5 tendons (p<0.05) 
(online supplemental table 6).
There was no statistically significant difference in the 
proportion of TSH or TPD ≥1 in HS with manual professions, 
or in those who practice sports or hobbies which may have 
high impact on the upper limbs (online supplemental tables 7 
and 8).
Patients with RA
Patients with RA were matched with 144 HS by age (within 
2 years) and sex, and with smoking status in 116/144 HS. TS 
as defined by TSH and power Doppler grade ≥1 in DF and 
ECU tendons was more prevalent in patients with RA (52.8%) 
compared with HS (0.9%). There were significantly more TSH 
and TPD grade ≥1 detected in patients with RA compared with 
age- matched and sex- matched HS (p=0.002 to <0.001) (online 
supplemental table 9).
DISCUSSION
Our study is the first to assess tendon involvement in large 
numbers of HS, encompassing the age incidence of RA with 
367 HS over 50 years, and showing a very low prevalence of 
abnormal findings. The few abnormalities observed were almost 
exclusively grade 1 in severity. Due to the large population 
assessed, we provide conclusive data validating and expanding 
on the findings of existing studies with few HS.16–18
TEF was more prevalent than TSH or TPD in HS. Although 
MRI studies have suggested TEF to be almost ubiquitous in 
DF tendons in HS,19 we have shown that ultrasound detects 
smaller numbers: less than 2% of DF tendons even in the older 
age group. Visualisation of tendons in two dimensions is the 
most likely cause of this difference. Tenosynovial abnormalities 
on ultrasound were significantly more prevalent in early RA 
compared with matched HS.
By explicitly selecting only subjects with minimal joint pain 
and without overt osteoarthritis, and by using a non- random 









RA versus age- matched and 
sex- matched HS*
P value
n 405 350 184 144
Age (years), median (IQR) 29 (25–33) 49 (44–54) 68 (62–72) <0.001 54 (45–67) 1.000
Female, n (%) 268 (66.2) 285 (81.4) 117 (63.6) <0.001 106 (73.6) 0.924
BMI, median (IQR) 23 (22–24) 25 (21–28) 26 (23–28) <0.001 27 (24–32) <0.001
Smoking
  Never (%) 316 (78) 241 (68) 115 (63) 68 (47) 0.021
  Ever (%) 88 (22) 109 (31) 66 (36) 75 (52)
  Current (%) 47 (12) 56 (16) 12 (7) 28 (19)
EMS (min), median (IQR) n/a n/a n/a n/a 60 (15–120) n/a
Symptom duration (weeks), median (IQR) n/a n/a n/a n/a 26 (13–52) n/a
CRP (mg/L), median (IQR) n/a n/a n/a n/a 7 (3–20) n/a
DAS28 CRP, median (IQR) n/a n/a n/a n/a 5.1 (4.1–5.8) n/a
Tender joint,† median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) n/a 17 (11–27) <0.001
Swollen joint,† median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) n/a 6 (3–11) <0.001
DF 1 TSH grade ≥1, n (%) 1 (0.1) 0 (0) 1 (0.3) 0.490 15 (5.2) <0.001
DF 2 TSH grade ≥1, n (%) 1 (0.1) 2 (0.3) 0 (0) 0602 50 (17.3) <0.001
DF 3 TSH grade ≥1, n (%) 2 (0.2) 1 (0.1) 2 (0.6) 0.432 50 (17.3) <0.001
DF 4 TSH grade ≥1, n (%) 2 (0.2) 1 (0.1) 1 (0.3) 1.000 28 (9.8) <0.001
DF 5 TSH grade ≥1, n (%) 1 (0.1) 4 (0.6) 0 (0) 0.220 36 (12.5) <0.001
ECU TSH grade ≥1, n (%) 7 (0.9) 9 (1.3) 1 (0.3) 0.293 65 (22.6) <0.001
DF 1 TPD grade ≥1, n (%) 1 (0.1) 0 (0) 1 (0.3) 0.490 10 (3.5) 0.002
DF 2 TPD grade ≥1, n (%) 0 (0) 1 (0.1) 0 (0) 0.568 36 (12.6) <0.001
DF 3 TPD grade ≥1, n (%) 1 (0.1) 0 (0) 0 (0) 1.000 40 (13.9) <0.001
DF 4 TPD grade ≥1, n (%) 0 (0) 0 (0) 1 (0.3) 0.194 20 (7) <0.001
DF 5 TPD grade ≥1, n (%) 0 (0) 0 (0) 0 (0) n/a 23 (8.1) <0.001
ECU TPD grade≥1, n (%) 0 (0) 0 (0) 0 (0) n/a 62 (21.7) <0.001
Total grade tendon score,‡ mean (range) 0.04 (0-2) 0.05 (0-4) 0.04 (0-2) 3.02 (0-21)
Total count of tendons grade ≥1,§ mean (range) 0.03 (0-2) 0.05 (0-4) 0.03 (0-2) 1.69 (0-11)
Individuals with grade ≥1 TSH, n (%) 12 (3.0) 10 (2.8) 4 (2.1) 76 (52.8)
Individuals with grade ≥1 TPD, n (%) 2 (0.5) 1 (0.3) 2 (1.1) 63 (43.7)
Individuals with grade ≥1 TEF, n (%) 50 (12.2) 46 (13.2) 29 (15.8) n/a
*RA and HS age matched and sex matched to compare ultrasound graded tendon findings.
†Patients with RA had 66/68 joint counts; HS had joint counts of MCPs, PIPs, wrists and MTPs.
‡Total grade tendon score is the per patient sum of all grades of TSH and TPD tendon abnormalities.
§ Total count of tendons grade ≥1 includes TSH and TPD.
BMI, body mass index; CRP, C reactive protein; DAS28, Disease Activity Score in 28 joints; DF, digit flexor; ECU, extensor carpi ulnaris; EMS, early morning stiffness; HS, healthy 
subjects; M, middle; MCP, metacarpophalangeal; MTP, metatarsophalangeal; O, old; PIP, proximal interphalangeal; RA, rheumatoid arthritis; TEF, tenosynovial effusion; TPD, 
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recruitment strategy to ensure inclusion of an older cohort, HS 
in this study may have fewer tendon changes than an unselected 
general population of 60–80 year olds. However, it was not our 
purpose to document the presence of tendon abnormalities in 
unselected primary or secondary care early arthritis clinics or in 
osteoarthritis, but to assess if HS with no symptoms may have 
ultrasound inflammatory abnormalities. The lack of a formal 
reliability study which would have been logistically difficult 
in such a large study, and the consecutive, not blinded recruit-
ment may be seen as potential limitations. We mitigated these 
by designing a blinded central regrading strategy of the first HS 
scan performed by each centre.20
The very low prevalence of TSH and TPD across a large age 
range in HS suggests that these findings can be seen as poten-
tially pathological, and not simply the consequence of ageing, 
by health professionals performing ultrasound in early arthritis 
or disease management clinics. The interpretation of such find-
ings should depend on the clinical context. In addition, DF and 
ECU tendons can be easily examined during routine ultrasound 
examination and so could be included in abbreviated scanning 
protocols.
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